EARNINGS PER SHARE The following table presents the computation of basic and diluted earnings per share for the years ended September 30, 2023, 2022 and 2021. | | | | | | | | | | | | | | | | | | | | | | | Year Ended September 30, | | | 2023 | | 2022 | | 2021 | | | (in thousands, except per share amounts) | Numerator: | | | | | | | Net loss attributable to Arrowhead Pharmaceuticals, Inc. | | $ | (205,275) | | | $ | (176,063) | | | $ | (140,848) | | | | | | | | | Denominator: | | | | | | | Weighted-average basic shares outstanding | | 106,750 | | | 105,426 | | | 103,745 | | Effect of dilutive securities | | — | | | — | | | — | | Weighted-average diluted shares outstanding | | 106,750 | | | 105,426 | | | 103,745 | | | | | | | | | Basic earnings per share | | $ | (1.92) | | | $ | (1.67) | | | $ | (1.36) | | Diluted earnings per share | | $ | (1.92) | | | $ | (1.67) | | | $ | (1.36) | |
Potentially dilutive securities representing approximately 4,053,000, 3,885,000 and 2,063,000 shares of common stock were excluded from the computation of diluted earnings per share for the years ended September 30, 2023, 2022 and 2021, respectively, because their effect would have been anti-dilutive.
|